LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome.

coexression network lncRNA myelodysplastic syndrome outcome pathogenesis progression

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
23 Sep 2020
Historique:
received: 18 08 2020
revised: 18 09 2020
accepted: 20 09 2020
entrez: 26 9 2020
pubmed: 27 9 2020
medline: 27 9 2020
Statut: epublish

Résumé

myelodysplastic syndrome (MDS) is a hematopoietic stem cell disorder with an incompletely known pathogenesis. Long noncoding RNAs (lncRNAs) play multiple roles in hematopoiesis and represent a new class of biomarkers and therapeutic targets, but information on their roles in MDS is limited. here, we aimed to characterize lncRNAs deregulated in MDS that may function in disease pathogenesis. In particular, we focused on the identification of lncRNAs that could serve as novel potential biomarkers of adverse outcomes in MDS. we performed microarray expression profiling of lncRNAs and protein-coding genes (PCGs) in the CD34+ bone marrow cells of MDS patients. Expression profiles were analyzed in relation to different aspects of the disease (i.e., diagnosis, disease subtypes, cytogenetic and mutational aberrations, and risk of progression). LncRNA-PCG networks were constructed to link deregulated lncRNAs with regulatory mechanisms associated with MDS. we found several lncRNAs strongly associated with disease pathogenesis (e.g., H19, WT1-AS, TCL6, LEF1-AS1, EPB41L4A-AS1, PVT1, GAS5, and ZFAS1). Of these, downregulation of LEF1-AS1 and TCL6 and upregulation of H19 and WT1-AS were associated with adverse outcomes in MDS patients. Multivariate analysis revealed that the predominant variables predictive of survival are blast count, H19 level, and TP53 mutation. Coexpression network data suggested that prognosis-related lncRNAs are predominantly related to cell adhesion and differentiation processes (H19 and WT1-AS) and mechanisms such as chromatin modification, cytokine response, and cell proliferation and death (LEF1-AS1 and TCL6). In addition, we observed that transcriptional regulation in the H19/IGF2 region is disrupted in higher-risk MDS, and discordant expression in this locus is associated with worse outcomes. we identified specific lncRNAs contributing to MDS pathogenesis and proposed cellular processes associated with these transcripts. Of the lncRNAs associated with patient prognosis, the level of H19 transcript might serve as a robust marker comparable to the clinical variables currently used for patient stratification.

Sections du résumé

BACKGROUND BACKGROUND
myelodysplastic syndrome (MDS) is a hematopoietic stem cell disorder with an incompletely known pathogenesis. Long noncoding RNAs (lncRNAs) play multiple roles in hematopoiesis and represent a new class of biomarkers and therapeutic targets, but information on their roles in MDS is limited.
AIMS OBJECTIVE
here, we aimed to characterize lncRNAs deregulated in MDS that may function in disease pathogenesis. In particular, we focused on the identification of lncRNAs that could serve as novel potential biomarkers of adverse outcomes in MDS.
METHODS METHODS
we performed microarray expression profiling of lncRNAs and protein-coding genes (PCGs) in the CD34+ bone marrow cells of MDS patients. Expression profiles were analyzed in relation to different aspects of the disease (i.e., diagnosis, disease subtypes, cytogenetic and mutational aberrations, and risk of progression). LncRNA-PCG networks were constructed to link deregulated lncRNAs with regulatory mechanisms associated with MDS.
RESULTS RESULTS
we found several lncRNAs strongly associated with disease pathogenesis (e.g., H19, WT1-AS, TCL6, LEF1-AS1, EPB41L4A-AS1, PVT1, GAS5, and ZFAS1). Of these, downregulation of LEF1-AS1 and TCL6 and upregulation of H19 and WT1-AS were associated with adverse outcomes in MDS patients. Multivariate analysis revealed that the predominant variables predictive of survival are blast count, H19 level, and TP53 mutation. Coexpression network data suggested that prognosis-related lncRNAs are predominantly related to cell adhesion and differentiation processes (H19 and WT1-AS) and mechanisms such as chromatin modification, cytokine response, and cell proliferation and death (LEF1-AS1 and TCL6). In addition, we observed that transcriptional regulation in the H19/IGF2 region is disrupted in higher-risk MDS, and discordant expression in this locus is associated with worse outcomes.
CONCLUSIONS CONCLUSIONS
we identified specific lncRNAs contributing to MDS pathogenesis and proposed cellular processes associated with these transcripts. Of the lncRNAs associated with patient prognosis, the level of H19 transcript might serve as a robust marker comparable to the clinical variables currently used for patient stratification.

Identifiants

pubmed: 32977510
pii: cancers12102726
doi: 10.3390/cancers12102726
pmc: PMC7598221
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Agentura Pro Zdravotnický Výzkum České Republiky
ID : 17-31398A
Organisme : Grantová Agentura České Republiky
ID : 20-19162S
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : 00023736

Références

Eur J Hum Genet. 2011 Mar;19(3):313-9
pubmed: 21150891
Bioinformatics. 2017 Sep 1;33(17):2622-2630
pubmed: 28472271
J Exp Med. 2014 Aug 25;211(9):1821-32
pubmed: 25135298
Cell Prolif. 2014 Jun;47(3):189-99
pubmed: 24738971
Nat Med. 2006 Oct;12(10):1191-7
pubmed: 17063141
Oncogene. 2007 May 3;26(20):2840-50
pubmed: 17160024
Blood. 1994 Nov 1;84(9):3071-9
pubmed: 7949179
Oncotarget. 2015 Oct 6;6(30):29209-23
pubmed: 26353930
Clin Epigenetics. 2018 Apr 10;10:47
pubmed: 29643943
Blood Adv. 2017 Aug 16;1(19):1505-1516
pubmed: 29296792
Br J Haematol. 2010 May;149(3):451-4
pubmed: 20085581
Oncogene. 2000 May 25;19(23):2796-802
pubmed: 10851082
J Hematol Oncol. 2011 Jan 06;4:1
pubmed: 21211043
Oncogene. 2008 Feb 28;27(10):1449-60
pubmed: 17724462
Plant Mol Biol. 2012 Jan 31;:
pubmed: 22290409
J Clin Oncol. 2013 Oct 1;31(28):3557-64
pubmed: 24002510
Genome Res. 2012 Sep;22(9):1775-89
pubmed: 22955988
Blood Cancer J. 2015 Jul 31;5:e333
pubmed: 26230957
Front Oncol. 2019 Nov 06;9:1173
pubmed: 31781490
RNA. 2007 Dec;13(12):2287-99
pubmed: 17940140
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Mol Cancer. 2015 Apr 01;14:73
pubmed: 25889562
Oncotarget. 2017 Jan 24;8(4):5789-5799
pubmed: 27494890
Cancer Res. 2008 Jan 1;68(1):44-54
pubmed: 18172295
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Drugs. 2016 May;76(8):889-900
pubmed: 27193945
Jpn J Cancer Res. 2000 Jun;91(6):597-603
pubmed: 10874211
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
pubmed: 24030381
J Cell Mol Med. 2019 Apr;23(4):3021-3025
pubmed: 30770626
Int J Hematol. 2009 Mar;89(2):173-187
pubmed: 19152102
Leuk Res. 2015 Aug;39(8):866-73
pubmed: 26012361
Acta Haematol. 2017;137(1):32-39
pubmed: 27866185

Auteurs

Katarina Szikszai (K)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.

Zdenek Krejcik (Z)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.

Jiri Klema (J)

Department of Computer Science, Czech Technical University, 121 35 Prague, Czech Republic.

Nikoleta Loudova (N)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.

Andrea Hrustincova (A)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
Faculty of Science, Charles University, 128 00 Prague, Czech Republic.

Monika Belickova (M)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.

Monika Hruba (M)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic.

Jitka Vesela (J)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.

Viktor Stranecky (V)

First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic.

David Kundrat (D)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.

Pavla Pecherkova (P)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.

Jaroslav Cermak (J)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.

Anna Jonasova (A)

General University Hospital, 128 08 Prague, Czech Republic.

Michaela Dostalova Merkerova (M)

Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.

Classifications MeSH